Literature DB >> 14557473

Intronic single nucleotide polymorphisms in the RET protooncogene are associated with a subset of apparently sporadic pheochromocytoma and may modulate age of onset.

Sarah R McWhinney1, Getachew Boru, Philip K Binkley, Mariola Peczkowska, Andrzej A Januszewicz, Hartmut P H Neumann, Charis Eng.   

Abstract

Approximately 75% of pheochromocytomas are sporadic. Germline mutations in RET, VHL, SDHB, and SDHD have been shown to cause the 25% that are hereditary. Germline high penetrance gain-of-function RET mutations cause multiple endocrine neoplasia type 2, of which medullary thyroid carcinoma (MTC) and pheochromocytoma are components, whereas loss-of-function mutations cause Hirschprung disease (HSCR). A low-penetrance founder locus, in linkage disequilibrium with a RET ancestral haplotype comprising specific alleles at three intron (IVS) 1 single nucleotide polymorphisms (SNPs) (haplotype 0) and SNP A45A, predisposes to the majority of isolated HSCR. A different low-penetrance locus, in linkage disequilibrium with IVS 1 haplotype 2 and SNP S836S, was associated with a subset of sporadic MTC. We, therefore, sought to determine whether RET might also be a low-penetrance gene for apparently sporadic pheochromocytoma. We analyzed 104 pheochromocytoma cases without germline mutations in RET, VHL, SDHD, and SDHB for their status at A45, S836, three IVS 1 SNPs, and a novel upstream insertion/deletion variant. Pheochromocytoma cases were not associated with either A45A or S836S, but we found that cases were associated with haplotype 0 (P = 0.032). However, unlike HSCR, this pheochromocytoma-associated haplotype 0 was not associated with A45A. Taken together with the strengthening of association with the addition of the 5' insertion/deletion variant data (P = 0.016), our observations suggest the presence of a low-penetrance pheochromocytoma susceptibility locus in a region upstream of the putative loci for HSCR and apparently sporadic MTC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557473     DOI: 10.1210/jc.2003-030245

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population.

Authors:  A K Siraj; M Al-Rasheed; M Ibrahim; K Siddiqui; F Al-Dayel; O Al-Sanea; S Uddin; K Al-Kuraya
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

2.  Mutations and polymorphisms in the SDHB, SDHD, VHL, and RET genes in sporadic and familial pheochromocytomas.

Authors:  Jens Waldmann; Peter Langer; Nils Habbe; Volker Fendrich; Anette Ramaswamy; Matthias Rothmund; Detlef K Bartsch; Emily P Slater
Journal:  Endocrine       Date:  2009-04-28       Impact factor: 3.633

3.  Variation in WNT genes is associated with non-syndromic cleft lip with or without cleft palate.

Authors:  Brett T Chiquet; Susan H Blanton; Amber Burt; Deqiong Ma; Samuel Stal; John B Mulliken; Jacqueline T Hecht
Journal:  Hum Mol Genet       Date:  2008-04-14       Impact factor: 6.150

4.  CRISPLD2: a novel NSCLP candidate gene.

Authors:  Brett T Chiquet; Andrew C Lidral; Samuel Stal; John B Mulliken; Lina M Moreno; Mauricio Arcos-Burgos; Mauricio Arco-Burgos; Consuelo Valencia-Ramirez; Susan H Blanton; Jacqueline T Hecht
Journal:  Hum Mol Genet       Date:  2007-07-05       Impact factor: 6.150

5.  Genomic screening identifies novel linkages and provides further evidence for a role of MYH9 in nonsyndromic cleft lip and palate.

Authors:  Brett T Chiquet; Syed S Hashmi; Robin Henry; Amber Burt; John B Mulliken; Samuel Stal; Molly Bray; Susan H Blanton; Jacqueline T Hecht
Journal:  Eur J Hum Genet       Date:  2008-08-20       Impact factor: 4.246

6.  Case Report of a Prolactinoma in a Patient With a Novel MAX Mutation and Bilateral Pheochromocytomas.

Authors:  Kelly Lauter Roszko; Erica Blouch; Michael Blake; James F Powers; Arthur S Tischler; Richard Hodin; Peter Sadow; Elizabeth A Lawson
Journal:  J Endocr Soc       Date:  2017-10-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.